Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Novo Nordisk ( (NVO) ) has issued an announcement.
On November 11, 2024, Novo Nordisk launched a share repurchase programme as part of a broader initiative to repurchase shares worth up to DKK 20 billion over a 12-month period starting February 6, 2024. As of January 10, 2025, the company had repurchased 23,193,366 B shares at an average price of DKK 820.76, totaling DKK 19,036,102,830. This strategic move aims to strengthen the company’s financial positioning and enhance shareholder value, with Novo Nordisk currently holding 24,337,924 B shares as treasury shares, representing 0.5% of its share capital.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. The company focuses on defeating serious chronic diseases, particularly in the field of diabetes. Novo Nordisk pioneers scientific breakthroughs, expands access to medicines, and works to prevent and ultimately cure diseases. It employs approximately 72,000 people across 80 countries and markets its products in about 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
YTD Price Performance: -7.24%
Average Trading Volume: 6,874,981
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $362.6B
Learn more about NVO stock on TipRanks’ Stock Analysis page.
